JP2017520620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520620A5 JP2017520620A5 JP2017515874A JP2017515874A JP2017520620A5 JP 2017520620 A5 JP2017520620 A5 JP 2017520620A5 JP 2017515874 A JP2017515874 A JP 2017515874A JP 2017515874 A JP2017515874 A JP 2017515874A JP 2017520620 A5 JP2017520620 A5 JP 2017520620A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- exposed
- sdg
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 101
- SBVBJPHMDABKJV-PGCJWIIOSA-N secoisolariciresinol diglucoside Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-PGCJWIIOSA-N 0.000 claims description 48
- 239000004480 active ingredient Substances 0.000 claims description 41
- DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 claims description 36
- AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 claims description 36
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 claims description 36
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 claims description 36
- 231100000357 carcinogen Toxicity 0.000 claims description 34
- 239000003183 carcinogenic agent Substances 0.000 claims description 34
- 230000005855 radiation Effects 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 30
- 230000000975 bioactive effect Effects 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 23
- 230000006378 damage Effects 0.000 claims description 20
- 238000002405 diagnostic procedure Methods 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 9
- 206010012335 Dependence Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 230000000711 cancerogenic effect Effects 0.000 claims description 8
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 206010064912 Malignant transformation Diseases 0.000 claims description 6
- -1 hypochlorite ions Chemical class 0.000 claims description 6
- 230000036212 malign transformation Effects 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 238000002591 computed tomography Methods 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 229910052704 radon Inorganic materials 0.000 claims description 4
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000779 smoke Substances 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 231100000167 toxic agent Toxicity 0.000 claims description 4
- 239000003440 toxic substance Substances 0.000 claims description 4
- 208000032484 Accidental exposure to product Diseases 0.000 claims description 3
- 231100000818 accidental exposure Toxicity 0.000 claims description 3
- 241000208125 Nicotiana Species 0.000 claims description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 2
- 239000010425 asbestos Substances 0.000 claims description 2
- 229910052895 riebeckite Inorganic materials 0.000 claims description 2
- PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 claims 10
- OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 claims 10
- 235000004239 secoisolariciresinol Nutrition 0.000 claims 10
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462005330P | 2014-05-30 | 2014-05-30 | |
| US62/005,330 | 2014-05-30 | ||
| US201562101296P | 2015-01-08 | 2015-01-08 | |
| US62/101,296 | 2015-01-08 | ||
| PCT/US2015/033501 WO2015184441A2 (en) | 2014-05-30 | 2015-06-01 | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020068332A Division JP2020121987A (ja) | 2014-05-30 | 2020-04-06 | 放射線および化学損傷に対する保護のためのセコイソラリシレジノールジグルコシド（ｓｄｇ）および関連化合物の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017520620A JP2017520620A (ja) | 2017-07-27 |
| JP2017520620A5 true JP2017520620A5 (enExample) | 2018-07-12 |
Family
ID=54700083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515874A Pending JP2017520620A (ja) | 2014-05-30 | 2015-06-01 | 放射線および化学損傷に対する保護のためのセコイソラリシレジノールジグルコシド（ｓｄｇ）および関連化合物の使用 |
| JP2020068332A Pending JP2020121987A (ja) | 2014-05-30 | 2020-04-06 | 放射線および化学損傷に対する保護のためのセコイソラリシレジノールジグルコシド（ｓｄｇ）および関連化合物の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020068332A Pending JP2020121987A (ja) | 2014-05-30 | 2020-04-06 | 放射線および化学損傷に対する保護のためのセコイソラリシレジノールジグルコシド（ｓｄｇ）および関連化合物の使用 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3148560A4 (enExample) |
| JP (2) | JP2017520620A (enExample) |
| KR (1) | KR20170010019A (enExample) |
| CN (2) | CN107155304A (enExample) |
| AU (2) | AU2015266614A1 (enExample) |
| CA (1) | CA2950744A1 (enExample) |
| IL (1) | IL249219A0 (enExample) |
| MA (1) | MA39899A (enExample) |
| WO (1) | WO2015184441A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071746B2 (en) | 2016-06-07 | 2021-07-27 | The Trustees Of The University Of Pennsylvania | Compositions and methods for protecting organs from ischemia/reperfusion injury associated with transplantation |
| EP3606325B1 (en) * | 2017-04-03 | 2024-09-04 | Gusto Global, LLC | Rational design of microbial-based biotherapeutics |
| US20200268779A1 (en) * | 2017-09-27 | 2020-08-27 | The Trustees Of The University Of Pennsylvania | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTION |
| US20210128596A1 (en) * | 2017-09-27 | 2021-05-06 | University Of Pennsylvania | Compositions and methods for treating septic cardiomyopathy |
| EP3843557B1 (en) * | 2018-08-31 | 2023-09-20 | Innophos, LLC | An extract of anacardium occidentale for use in treating oxidation induced dna damage |
| CN116850162A (zh) * | 2023-08-08 | 2023-10-10 | 南通大学附属医院 | 肠二醇在制备治疗放射性肠炎药物中的应用 |
| CN121094806B (zh) * | 2025-11-07 | 2026-02-24 | 深圳鼎智通讯股份有限公司 | 一种Android SoftPOS可信应用方法以及应用系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6486126B1 (en) * | 1999-06-30 | 2002-11-26 | University Of Saskatchewan Technologies Incorporated | Antioxidant activity in SDG metabolites |
| EP1414436A1 (en) * | 2000-06-14 | 2004-05-06 | Alla Shapiro | Radioprotective agents |
| CN100365005C (zh) * | 2006-03-02 | 2008-01-30 | 江南大学 | 一种从亚麻籽中提取纯化开环异落叶松树脂酚二葡萄糖苷的方法 |
| US20070293458A1 (en) * | 2006-06-16 | 2007-12-20 | Ip-6 Research Inc. | Prevention of nuclear, solar, and other radiation-induced tissue damage |
| US10449224B2 (en) * | 2007-05-25 | 2019-10-22 | The Trustees Of The University Of Pennsylvania | Flaxseed lignan complex, methods of using and compositions thereof |
| AU2009279676C1 (en) * | 2008-08-07 | 2015-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Radioprotectants targeting thrombospondin-1 and CD47 |
| CN101759731B (zh) * | 2008-12-25 | 2011-10-19 | 中国科学院兰州化学物理研究所 | 亚麻籽胶和开环异落叶松树脂酚二葡萄糖苷的提取方法 |
| PT3007557T (pt) * | 2013-06-10 | 2018-11-09 | Scripps Research Inst | Preparação do diglucosídeo (s,s)-secoisolariciresinol e do diglucosídeo (r,r)-secoisolariciresinol |
-
2015
- 2015-06-01 CN CN201580028874.0A patent/CN107155304A/zh active Pending
- 2015-06-01 WO PCT/US2015/033501 patent/WO2015184441A2/en not_active Ceased
- 2015-06-01 EP EP15799095.3A patent/EP3148560A4/en not_active Withdrawn
- 2015-06-01 JP JP2017515874A patent/JP2017520620A/ja active Pending
- 2015-06-01 AU AU2015266614A patent/AU2015266614A1/en not_active Abandoned
- 2015-06-01 CN CN202010760162.0A patent/CN112336736A/zh active Pending
- 2015-06-01 CA CA2950744A patent/CA2950744A1/en not_active Abandoned
- 2015-06-01 MA MA039899A patent/MA39899A/fr unknown
- 2015-06-01 KR KR1020167037042A patent/KR20170010019A/ko not_active Withdrawn
-
2016
- 2016-11-27 IL IL249219A patent/IL249219A0/en unknown
-
2020
- 2020-04-06 JP JP2020068332A patent/JP2020121987A/ja active Pending
- 2020-11-16 AU AU2020270469A patent/AU2020270469A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017520620A5 (enExample) | ||
| RU2769397C2 (ru) | Композиции и способы лечения передозировки опиоидами | |
| Newhouse et al. | Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma | |
| Chen et al. | Supervised physical training enhances muscle strength but not muscle mass in prostate cancer patients undergoing androgen deprivation therapy: a systematic review and meta-analysis | |
| HU230656B1 (hu) | Daptomicin alkalmazása | |
| DE112015001251T5 (de) | Nasale Arzneimittelprodukte und Verfahren zu deren Verwendung | |
| JP2017501201A5 (enExample) | ||
| CN109394743A (zh) | 用于治疗真菌感染的新的药物组合物 | |
| EP3807245B1 (en) | Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| Gilani et al. | Comparison of post-operative atelectasis in patients undergoing coronary artery bypass grafting with and without pre-operative incentive spirometry | |
| JP2014201591A (ja) | 医用画像処理電離放射線被曝の長期的および短期的な有害な影響をゲニステインの投与により軽減する方法 | |
| Lee et al. | A phase 3 randomized clinical trial to compare efficacy and safety between combination therapy and monotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10) | |
| Gallello et al. | Poisoning histories in the Italian renaissance: the case of Pico Della Mirandola and Angelo Poliziano | |
| Hanon et al. | Irreversible acinar airway abnormality in well controlled asthma | |
| Karadag et al. | Pulmonary fibrosis developed secondary to methotrexate use in a patient with psoriasis vulgaris | |
| Winiarczyk et al. | Breakthrough pain in cancer patients | |
| JP2016503063A5 (enExample) | ||
| WO2023281007A1 (en) | Melflufen for use in the treatment of multiple myeloma | |
| JP2018528208A5 (enExample) | ||
| EP4302787B1 (en) | Hydroxyethycellulose gel compositions comprising bacteriophages | |
| KR102063397B1 (ko) | Pfi-3를 포함하는 폐암 또는 대장암의 예방 또는 치료용 조성물 | |
| KR20250160957A (ko) | 척수성 근위축증의 치료를 위한 조성물 및 방법 | |
| US20180243327A1 (en) | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION DAMAGE | |
| Ricci et al. | D23 PEDIATRIC RARE DISEASES AND LUNG DEVELOPMENT: A Phase 2 Clinical Trial Assessing Efficacy And Safety Of The Mtor Inhibitor Sirolimus In The Treatment Of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, And Gorham-Stout Disease | |
| RU2595881C2 (ru) | Применение нанофосфолипидной композиции рифампицина совместно с протионамидом или его нанофосфолипидной формой в лечении туберкулеза |